Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKEEGA vs CERUBIDINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.
Treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (m CRPC) in combination with prednisone.
Acute myeloid leukemia,Acute lymphoblastic leukemia,Chronic myeloid leukemia in blast crisis,Kaposi's sarcoma (off-label)
Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.
45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.
Terminal half-life: 17–30 hours (mean ~24 h); allows once-daily dosing but may require dose adjustment in renal impairment.
Triphasic elimination: initial half-life 30 min (distribution), intermediate 3-5 hours (metabolism), terminal half-life 20-30 hours (slow elimination from tissues). Clinically relevant for scheduling and myelosuppression monitoring.
Niraparib is primarily metabolized by carboxylesterases (CEs) and to a lesser extent by CYP1A2 and CYP2D6. Abiraterone acetate is hydrolyzed to abiraterone, which is then metabolized by CYP3A4 and CYP2D6.
Primarily hepatic metabolism via aldo-keto reductases to daunorubicinol (active metabolite), and further via CYP2D6 and carbonyl reductases.
Renal: ~85% (primarily as unchanged drug); Biliary/Fecal: ~15%.
Primarily hepatic metabolism with biliary excretion (about 40% as unchanged drug and metabolites in bile). Renal excretion accounts for approximately 8-15% of the dose as unchanged drug and metabolites. Fecal elimination is less than 20%.
~99% (bound primarily to α1-acid glycoprotein and albumin).
Approximately 50-70% bound to plasma proteins, primarily albumin.
Vd: ~1.5–2.0 L/kg (indicates extensive tissue distribution).
Volume of distribution is high, ranging from 15-30 L/kg, indicating extensive tissue binding and distribution, particularly into erythrocytes and tissues.
Oral: ~90% (high oral bioavailability).
Oral bioavailability is less than 5% due to extensive first-pass metabolism; therefore, not administered orally. IV administration results in 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Not recommended for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
Cr Cl 10–50 m L/min: reduce dose by 25%; Cr Cl <10 m L/min: reduce dose by 50%. Hemodialysis: administer after dialysis; dose reduction by 50%.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment; but monitor closely for toxicity.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients; no recommended dose.
25–45 mg/m² IV on days 1–3 every 21 days; neonates: <10 kg: 1 mg/kg IV daily for 3–5 days.
No specific dose adjustment required. Clinical studies included patients ≥65 years; increased risk of adverse effects such as hypertension, hypokalemia, and fatigue. Monitor renal function and electrolytes regularly.
Initiate at lower end of dose range (30 mg/m²/day for 3 days) due to increased myelotoxicity; monitor renal function.
AKEEGA can cause severe and persistent hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess, especially in patients with renal impairment. Monitor blood pressure, serum potassium, and fluid status regularly.
Severe myelosuppression; cumulative dose-related cardiotoxicity; extravasation with tissue necrosis; secondary leukemias.
Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess,Adrenocortical insufficiency,Hepatotoxicity,Cardiovascular effects including QT prolongation,Bone marrow suppression (anemia, thrombocytopenia, neutropenia),Fetal harm if used during pregnancy
Bone marrow suppression; cardiac toxicity (cumulative doses >550 mg/m²); hepatic and renal impairment; tumor lysis syndrome; immunosuppression.
Concomitant use with strong CYP3A4 inducers,Severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease,History of hypersensitivity to niraparib, abiraterone, or any excipient
Severe myelosuppression; previous anthracycline therapy at maximum cumulative dose; severe hepatic impairment; severe cardiac disease; pregnancy.
Avoid food and beverages containing grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and may increase abiraterone exposure. Take AKEEGA on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid high-fat meals as they increase abiraterone absorption.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing toxicity. No other specific food restrictions reported.
AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abiraterone acetate is also associated with fetal risks. First trimester exposure may cause embryofetal lethality and teratogenicity. Second and third trimester exposure may impair fetal adrenal function and androgen-dependent development.
Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal growth restriction, prematurity, and neonatal myelosuppression.
No data on the presence of niraparib or abiraterone in human milk, effects on breastfed infants, or milk production. Due to the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. M/P ratio is unknown.
Contraindicated during breastfeeding. Daunorubicin is excreted into breast milk; M/P ratio unknown due to limited data. Potential for severe adverse effects in nursing infant including immunosuppression, cardiotoxicity, and carcinogenesis.
No specific dose adjustments are established during pregnancy as AKEEGA is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate dose adjustments if used inadvertently, but no data are available. If exposure occurs, cautious monitoring and individualized dosing are recommended.
No established dosing adjustments for pregnancy. Standard dosing based on body surface area, but use only if clearly needed due to teratogenicity. Increased volume of distribution may alter pharmacokinetics, but formal dose modifications not defined.
AKEEGA (niraparib and abiraterone acetate) is indicated for BRCA-positive metastatic castration-resistant prostate cancer. Monitor for myelosuppression (CBC at baseline and monthly), hypertension (BP weekly for first month then monthly), hypokalemia, and hepatotoxicity (LFTs at baseline and monthly). CYP3A4 inhibitors increase abiraterone exposure; avoid strong inhibitors or reduce dose. Corticosteroid co-administration (prednisone 5 mg BID) is required to manage mineralocorticoid excess. Niraparib may cause fetal harm; confirm pregnancy status before initiation.
Cerubidine (daunorubicin) is an anthracycline antineoplastic antibiotic; premedicate with antiemetics; monitor for cardiotoxicity (cumulative dose limit 550 mg/m², or 450 mg/m² with prior chest radiation); administer via IV over 15-30 minutes to avoid extravasation (vesicant); observe for rapid lysis syndrome in high-tumor-burden patients; adjust dose for hepatic impairment (bilirubin >1.2 mg/d L).
Take tablets on an empty stomach, at least 1 hour before or 2 hours after a meal.,Swallow tablets whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit during treatment.,Use effective contraception during treatment and for 4 months after the last dose for females and 3 months for males.,Report signs of bone marrow suppression: fever, bruising, bleeding, or unusual tiredness.,Report symptoms of high blood pressure: severe headache, blurred vision, or chest pain.,Take prednisone exactly as prescribed; do not stop abruptly.,Avoid pregnancy; discuss fertility preservation options before starting treatment.,Take missed doses if within 12 hours of scheduled time; otherwise skip and resume next day.,Store at room temperature; keep in original container.
This drug may cause irreversible heart damage at high cumulative doses; report chest pain, shortness of breath, or swelling of ankles/feet.,You will need regular blood tests to monitor blood cell counts and heart function.,Notify your healthcare provider immediately if you experience pain, redness, or swelling at the injection site.,This medication can cause severe nausea and vomiting; antiemetic therapy will be given.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception; do not breastfeed while on this medication.,Your urine may appear reddish-orange for 1-2 days after treatment; this is harmless.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKEEGA vs CERUBIDINE, answered by our medical review team.
AKEEGA is a Antineoplastic Combination that works by Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.. CERUBIDINE is a Anthracycline antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II and preventing DNA replication and transcription, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKEEGA and CERUBIDINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKEEGA is: Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.. The standard adult dose of CERUBIDINE is: 45–60 mg/m² IV on days 1–3 every 21–28 days, or 30–60 mg/m² IV daily for 3 days every 3 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKEEGA and CERUBIDINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKEEGA is classified as Category C. AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abirate. CERUBIDINE is classified as Category C. Pregnancy Category D. First trimester: High risk of congenital malformations including craniofacial, skeletal, CNS, and cardiac defects. Second and third trimesters: Risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.